Growing Need for Companion Diagnostics is Evident at Drug Discovery Event
The momentum for targeted therapies has downstream implications for clinical laboratories
Already a member? Log in here
Diagnostics Pipeline: Expanded DPYD Test Anticipated to Make Chemotherapy Safer
Labcorp’s new genotyping test can identify gene variants that may make standard oncologic treatment deadly for some
Already a member? Log in here
FDA Watch: Natera, Valar Labs Receive FDA Clearances for Bladder Cancer Tests
Natera’s assay focuses on the need for adjuvant therapy, while Valar’s test stratifies risk of recurrence
Already a member? Log in here
Clarisa Blattner: The MRD Testing Reimbursement Challenge
Why operational readiness is becoming just as important as clinical innovation
Diagnostics Pipeline: To Gain Insight into Haystack MRD Test, Quest Works with City of Hope
New liquid biopsy assay will be used in conjunction with 500 cancer patients currently enrolled in clinical trials
Already a member? Log in here